Leidos Partnership continues successful
international MHS GENESIS Electronic Health Record deployment with
Wave Pacific
RESTON,
Va., Nov. 16, 2023 /PRNewswire/ -- The Leidos
Partnership for Defense Health (LPDH) today announced it
successfully delivered the MHS GENESIS electronic health record
(EHR) to an additional 7,000 Department of Defense (DOD) clinicians
and providers as part of a second Outside of the Contiguous United
States (OCONUS) deployment (Waves OKINAWA/S. KOREA). The current EHR deployment
spans 10 Military Treatment Facilities (MTFs) across Asia. The Pacific waves follow successful
deployments across European MTFs in September 2023 and deployment to all primary
state-side DOD facilities earlier this year.
"We're thrilled to continue our successful global roll-out of
the MHS GENESIS electronic health care record system," said
Liz Porter, Leidos Health Group
President. "Last month, our Partnership completed Wave Europe and
now we're pleased to deploy to Okinawa, South
Korea and other locations across the Pacific Rim. We look forward to 100% system
deployment early next year when the system goes live at the joint
DOD-Veterans Affairs Lovell Federal Health Care Center."
LPDH designed and developed MHS GENESIS, the Military Health
System's new EHR system, and has been providing program management
and technical expertise to the Program Executive Office Defense
Healthcare Management Systems since 2015.
With this latest overseas DOD wave deployment, the MHS GENESIS
system is now operational at over 3,700 locations and now reaches
over 183,000 users and 7.4 million DOD beneficiaries. MHS GENESIS
is 98% deployed to DOD garrison facilities.
"We're proud to complete yet another successful deployment,"
noted Chris Ruefer, Deputy Program
Executive Officer for DHMS. "In addition to achieving full global
deployment by early next year, we continue to optimize patient and
provider experiences, to include virtual health enhancements
planned for the future."
This deployment marked the last of 23 MHS GENESIS waves, with
each wave targeting a specific region and the DOD utilizing lessons
learned from prior waves to maximize subsequent wave efficiencies.
DOD will complete MHS GENESIS deployment to garrison facilities in
2024.
About Leidos
Leidos is a Fortune 500® technology, engineering, and science
solutions and services leader working to solve the world's toughest
challenges in the defense, intelligence, civil and health markets.
The company's 47,000 employees support vital missions for
government and commercial customers. Headquartered in Reston, Va., Leidos reported annual revenues
of approximately $14.4 billion for
the fiscal year ended December 30,
2022. For more information, visit www.leidos.com.
About LPDH
The Leidos Partnership consists of four core partners – Leidos,
Oracle Health, Accenture Federal Services and Henry Schein One – along with approximately 35
supporting businesses. Together, they deliver an integrated,
modern, secure health information system that includes an
electronic health record system, a dental system, identity
management capability, Cybersecurity, and other supporting
components. MHS GENESIS will serve as the system of record,
providing a single, integrated solution for managing the health and
military readiness of the force for DOD and the Department of
Veterans Affairs, among other agencies.
Certain statements in this announcement constitute
"forward-looking statements" within the meaning of the rules and
regulations of the U.S. Securities and Exchange Commission
(SEC). These statements are based on management's current
beliefs and expectations and are subject to significant risks
and uncertainties. These statements are not guarantees of
future results or occurrences. A number of factors could cause
our actual results, performance, achievements, or industry results
to be different from the results, performance, or achievements
expressed or implied by such forward-looking statements. These
factors include, but are not limited to, the "Risk Factors" set
forth in Leidos' Annual Report on Form 10-K for the fiscal year
ended December 30, 2022, and other
such filings that Leidos makes with the SEC from time to time.
Readers are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date hereof.
Leidos does not undertake to update forward-looking statements to
reflect the impact of circumstances or events that arise after the
date the forward-looking statements were made.
Contact:
Melissa Dueñas
(571) 526-6850
Melissa.L.Duenas@leidos.com
Thomas Doheny
(571) 474-4735
Dohenyt@leidos.com
Lauren Reddington
(202) 924-2226
Lauren.A.Reddington@leidos.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leidos-partnership-continues-mhs-genesis-overseas-deployment-in-second-planned-international-wave-301991286.html
SOURCE Leidos